Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Adv Sci (Weinh). 2024 Oct;11(38):e2402332. doi: 10.1002/advs.202402332. Epub 2024 Jul 25.
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are common hematological malignancies in adults. Despite considerable research advances, the development of standard therapies, supportive care, and prognosis for the majority of AML and ALL patients remains poor and the development of new effective therapy is urgently needed. Here, it is reported that activation of thermogenic adipose tissues (TATs) by cold exposure or β3-adrenergic receptor agonists markedly alleviated the development and progression of AML and ALL in mouse leukemia models. TAT activation (TATA) monotherapy substantially reduces leukemic cells in bone marrow and peripheral blood, and suppresses leukemic cell invasion, including hepatomegaly and splenomegaly. Notably, TATA therapy prolongs the survivals of AML- and ALL-bearing mice. Surgical removal of thermogenic brown adipose tissue (BAT) or genetic deletion of uncoupling protein 1 (UCP1) largely abolishes the TATA-mediated anti-leukemia effects. Metabolomic pathway analysis demonstrates that glycolytic metabolism, which is essential for anabolic leukemic cell growth, is severely impaired in TATA-treated leukemic cells. Moreover, a combination of TATA therapy with chemotherapy produces enhanced anti-leukemic effects and reduces chemotoxicity. These data provide a new TATA-based therapeutic paradigm for the effective treatment of AML, ALL, and likely other types of hematological malignancies.
急性髓细胞白血病 (AML) 和急性淋巴细胞白血病 (ALL) 是成人中常见的血液系统恶性肿瘤。尽管在研究方面取得了相当大的进展,为大多数 AML 和 ALL 患者制定了标准治疗方案、支持性护理和预后,但仍不理想,迫切需要开发新的有效治疗方法。在这里,据报道,通过寒冷暴露或β3-肾上腺素能受体激动剂激活生热脂肪组织 (TAT) 可显著缓解 AML 和 ALL 小鼠白血病模型的发展和进展。TAT 激活 (TATA) 单一疗法可显著减少骨髓和外周血中的白血病细胞,并抑制白血病细胞的侵袭,包括肝肿大和脾肿大。值得注意的是,TATA 治疗可延长 AML 和 ALL 荷瘤小鼠的存活时间。生热棕色脂肪组织 (BAT) 的手术切除或解偶联蛋白 1 (UCP1) 的基因缺失在很大程度上消除了 TATA 介导的抗白血病作用。代谢组学途径分析表明,糖酵解代谢对于合成代谢白血病细胞的生长至关重要,在 TATA 处理的白血病细胞中受到严重损害。此外,TATA 治疗与化疗相结合可产生增强的抗白血病作用并降低化疗毒性。这些数据为 AML、ALL 及可能其他类型的血液系统恶性肿瘤的有效治疗提供了一种新的基于 TATA 的治疗范例。